The FDA approved SKINVIVE by JUVÉDERM to reduce neck lines and improve neck appearance in adults over 21, giving AbbVie’s Allergan Aesthetics unit a new aesthetic treatment indication. The development is positive for the company’s product portfolio and commercialization prospects, but the immediate market impact is likely limited.
The FDA approved SKINVIVE by JUVÉDERM to reduce neck lines and improve neck appearance in adults over 21, giving AbbVie’s Allergan Aesthetics unit a new aesthetic treatment indication. The development is positive for the company’s product portfolio and commercialization prospects, but the immediate market impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
